Targeted therapy plus ablation for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two treatments: a targeted antibody therapy called nimotuzumab with chemotherapy, followed by a procedure that uses electrical pulses to destroy tumor cells. It is for people with locally advanced pancreatic cancer that has not spread, and aims to see if this approach can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pancreatic cancer that is confirmed by a biopsy and has not spread to other organs.
- You have not had chemotherapy or other whole-body cancer treatments before.
- Your overall health is reasonably good (able to do daily activities with some effort), and your blood counts and liver/kidney tests are within acceptable ranges.
- You do not have other serious medical conditions, active infections, or a history of another cancer (except cured skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (nimotuzumab, nab-paclitaxel, and gemcitabine) given before and after surgery for pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach improves outcomes.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether adding a targeted drug (nimotuzumab) to standard chemotherapy after surgery can help prevent pancreatic cancer from coming back. It is designed for people who have had their pancreatic cancer completely or nearly completely removed.
This trial tests combining nimotuzumab with chemotherapy (nab-paclitaxel and gemcitabine) after surgery to prevent pancreatic cancer from returning. It is for people whose tumors have a protein called EGFR, and whose cancer was removed with clear or close margins.
This trial tests adding nimotuzumab (a targeted therapy) to standard chemotherapy for people whose pancreatic cancer was completely removed with surgery. The goal is to see if this combination helps prevent the cancer from coming back.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Hear when a new Pancreatic Cancer, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.